Challenges of the Brazilian Public Policy for Hepatitis in 2013

Fábio Mesquita
Director
Department of STDs, AIDS, and Viral Hepatitis
Secretariat of Health Surveillance
Ministry of Health of Brazil
Innovation

Scientific Evidence

Dialogue with all stakeholders

SUS – Unified Health System
Create a specific coordination

Improve strategic information

Focus on diagnosis for VH key populations

Simplify access to treatment

Keep world leadership among developing countries
<table>
<thead>
<tr>
<th>REGIONS/STATE</th>
<th>NORTH</th>
<th>NORTH-EAST</th>
<th>MID-WEST</th>
<th>SOUTH-EAST</th>
<th>SÃO PAULO</th>
<th>SOUTH</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of treatments initiated by 20/12/13</td>
<td>135</td>
<td>231</td>
<td>191</td>
<td>178</td>
<td>920</td>
<td>262</td>
<td>1,917</td>
</tr>
</tbody>
</table>
HIGH LEVEL MEETING TO DISCUSS FUTURE TREATMENT OF HEPATITIS C
OTHER ISSUES FOR 2014

- Publication of joint Ordinance with SVS (DDAHV)-ANVISA-SCIT
- Improvement of the Laboratory
- New Technical Advisory Committee
- Possible revision of the CPTG (Clinical Protocol and Treatment Guidelines)
- Discussion of the possible incorporation of new drugs in 2014
Access Strategies:

- Differential pricing
- Licence agreements to generic manufacturers
- Medicines Patent Pool
- Local manufacturing in patent-free countries (freedom to operate)
- Patent opposition and local manufacturing
- Compulsory licensing
- Negotiation
- Productive Development Process – (Processo de Desenvolvimento Produtivo) (PDP)
Decision is a process that needs to consider:

1. Scientific Evidence;

2. Benefits x Harm;

3. Cost/Benefit
Thank you!

fabio.mesquita@aids.gov.br